Drug Profile
Small cell lung cancer vaccine - MabVax/MSKCC
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in USA (SC, Injection)
- 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
- 31 May 2011 Phase-I clinical trials in Small cell lung cancer in USA (SC)